文献速递生殖医学

胞饮突作为子宫内膜容受性标志物的临床验证:一项随机对照试验

Clinical validation of pinopode as a marker of endometrial receptivity: a randomized controlled trial.
PubMed 文献 · Fertil Steril · 2017-08-12

该研究分两阶段:第一阶段对363例首次IVF周期患者在黄体中期取子宫内膜行扫描电镜观察胞饮突并随访结局;第二阶段将136例至少两次胚胎种植失败患者随机分组,实验组按胞饮突评分行个体化胚胎移植,对照组常规冻融胚胎移植。结果显示胞饮突评分>85者临床妊娠率和持续妊娠率显著更高,个体化移植组临床妊娠率亦显著更高。

要点

  • 第一阶段363例首次IVF周期患者中,胞饮突评分>85者临床妊娠率74.29% vs 19.77%,持续妊娠率62.86% vs 11.86%,均显著更高。
  • 第二阶段136例至少两次种植失败患者中,个体化胚胎移植组临床妊娠率33.82% vs 对照组8.11%,显著更高。
  • 作者认为胞饮突评分是可靠的子宫内膜容受性标志物,基于评分的个体化移植对反复种植失败是有前景的解决方案。

核心结论

  • 胞饮突评分是可靠的子宫内膜容受性标志物,基于胞饮突评分的个体化胚胎移植对反复种植失败是有前景的解决方案。

研究设计与样本

  • 随机对照试验,在学术生育中心进行;第一阶段2014年12月至2016年12月招募363例首次IVF周期患者,第二阶段招募136例至少两次既往胚胎种植失败患者。
  • 第二阶段参与者按随机数字表分为两组,实验组例数为对照组的两倍;实验组行个体化胚胎移植,对照组常规行冻融胚胎移植。

主要发现

  • 第一阶段经受试者工作特征曲线分析,成功临床妊娠的最佳胞饮突评分为85。
  • 第一阶段胞饮突评分>85的患者临床妊娠率74.29% vs 19.77%,持续妊娠率62.86% vs 11.86%,均显著更高。
  • 第二阶段个体化胚胎移植组临床妊娠率33.82% vs 对照组8.11%,显著更高。

关键数值与推荐

  • 成功临床妊娠的最佳胞饮突评分为85(第一阶段受试者工作特征曲线分析)。
  • 胞饮突评分>85者临床妊娠率74.29% vs 19.77%,持续妊娠率62.86% vs 11.86%。
  • 第二阶段个体化胚胎移植组临床妊娠率33.82% vs 对照组8.11%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the clinical value of pinopodes in the human. DESIGN: Randomized controlled trial. SETTING: Academic fertility center. PATIENT(S): From December 2014 to December 2016, in a phase I trial, 363 patients were recruited in their first IVF cycles. In a phase II trial, 136 patients with at least two previous embryo implantation failures were recruited. INTERVENTION(S): In the phase I trial, in the midluteal phase, endometrial tissues were obtained for scanning electron microscopy, and their IVF treatment outcomes were followed up. In the phase II trial, participants were allocated into two groups by random number table, and the experimental group had twice the number of the control group. Individual ETs (iETs) were performed in the experimental group, while frozen-thawed embryos were routinely transferred in the control group. MAIN OUTCOME MEASURE(S): Clinical pregnancy rate (CPR) and ongoing pregnancy rate (OPR). RESULT(S): In the phase I trial, through receiver operation characteristic curve analysis, the optimal pinopode scoring for successful clinical pregnancy was determined to be 85. The CPR (74.29% vs. 19.77%) and OPR (62.86% vs 11.86%) were significantly higher in the patients whose pinopode scoring was >85. In the phase II trial, the CPR was dramatically higher in the iET group (33.82% vs. 8.11%). CONCLUSION(S): Pinopode scoring is a reliable marker of endometrial receptivity, and iET based on pinopode scoring is a promising solution for recurrent implantation failure. TRIAL REGISTRATION NUMBERS: ChiCTR-OOC-14005617; ChiCTR-OOC-15005882.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Qiong Z, Jie H, Yonggang W, et al. Clinical validation of pinopode as a marker of endometrial receptivity: a randomized controlled trial. Fertil Steril. 2017. PMID: 28807395. doi:10.1016/j.fertnstert.2017.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。